science
Revolution Medicines Reports Extended Survival in Pancreatic Cancer Trial
Revolution Medicines announced results from a Phase 3 study of its experimental drug daraxonrasib for advanced pancreatic adenocarcinoma. Patients treated with the drug had a median survival of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The company plans to seek FDA approval based on these findings.
Apr 17, 1:49 PM·1m read1 source
ST
news.google.comAudio version
Tap play to generate a narrated version.
Revolution Medicines reported results from a Phase 3 trial of its experimental drug daraxonrasib in patients with advanced pancreatic adenocarcinoma. 7 months. The company stated it intends to submit the data to the Food and Drug Administration for approval, though no specific timeline was provided.
Details and Expert Commentary Paul Oberstein, an investigator in the trial from NYU Langone’s Perlmutter Cancer Center, discussed the results on a biotech podcast.
He described the findings as potentially significant for pancreatic cancer treatment. Oberstein noted that pancreatic cancer is challenging to treat due to its aggressive nature and limited effective therapies.
“I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.”
Pancreatic cancer has low survival rates, with current treatments offering limited benefits for advanced stages. The trial involved patients with advanced disease, comparing daraxonrasib to standard chemotherapy. Revolution Medicines indicated that approval, if granted, could occur quickly following submission.
Steps The company plans to apply for Food and Drug Administration approval using the trial data.
Further details on the submission timeline were not announced. The results were presented as part of ongoing efforts to improve outcomes in pancreatic cancer.
